公开(公告)号：US10905772B2

公开(公告)日：2021-02-02

申请号：US15872841

申请日：2018-01-16

Applicant: AMGEN INC.

Inventor： Yuan Cheng ,  Chawita Netirojjanakul ,  Jerry Ryan Holder ,  Bin Wu ,  James R. Falsey ,  Bradley J. Herberich ,  Kelvin Sham ,  Leslie P. Miranda ,  Shu-Chen Lu ,  Murielle M. Veniant-Ellison ,  Shanaka Stanislaus ,  Junming Yie ,  Jing Xu

IPC: A61K47/68 ,  A61K38/26 ,  A61P3/10 ,  C07K16/28 ,  A61K39/395

Abstract: Methods of treating metabolic diseases and disorders using a composition comprising an antigen binding protein specific for the GIPR polypeptide conjugated to a GLP-1 receptor agonist are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy. In certain embodiments the composition comprises an antibody or functional fragment thereof comprising a cysteine at one or more conjugation site(s) wherein the GLP-1 receptor agonist is conjugated to the antibody or functional fragment thereof through the side-chain of the cysteine residue.

公开(公告)号：US20240052300A1

公开(公告)日：2024-02-15

申请号：US18266689

申请日：2021-12-21

Applicant: AMGEN RESEARCH (MUNCH) GMBH ,  AMGEN INC.

Inventor： Glenn Christopher Tan ,  Ewelina Zasadzinska ,  Patrick Hoffmann ,  Bin Wu

IPC: C12N5/00 ,  C12M3/06

CPC classification number: C12N5/0075 ,  C12M23/16

Abstract: The present disclosure provides materials and methods identifying, selecting, and characterizing cells that express and secrete non-Fc containing biomolecules.

公开(公告)号：US08772480B2

公开(公告)日：2014-07-08

申请号：US13681230

申请日：2012-11-19

Applicant: Amgen Inc.

Inventor： Kristin L. Andrews ,  Yunxin Y. Bo ,  Shon Booker ,  Victor J. Cee ,  Noel D'Angelo ,  Bradley J. Herberich ,  Fang-Tsao Hong ,  Claire L. M. Jackson ,  Brian Alan Lanman ,  Hongyu Liao ,  Longbin Liu ,  Nobuko Nishimura ,  Mark H. Norman ,  Liping H. Pettus ,  Anthony B. Reed ,  Adrian Leonard Smith ,  Seifu Tadesse ,  Nuria A. Tamayo ,  Bin Wu ,  Ryan Wurz ,  Kevin C. Yang

IPC: C07D401/04 ,  C07D401/14 ,  A61K31/444 ,  A61K31/53 ,  A61P35/00

CPC classification number: C07D473/00 ,  C07D401/14 ,  C07D405/14 ,  C07D413/14 ,  C07D417/14

Abstract: The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt thereof; methods of treating diseases or conditions, such as cancer, using the compounds; and pharmaceutical compositions containing the compounds, wherein the variables are as defined herein.

Abstract translation: 本发明涉及式I化合物或其药学上可接受的盐; 使用该化合物治疗疾病或病症如癌症的方法; 和含有这些化合物的药物组合物，其中变量如本文所定义。

公开(公告)号：US11732266B2

公开(公告)日：2023-08-22

申请号：US17080771

申请日：2020-10-26

Applicant: AMGEN INC.

Inventor： Michael Ollmann ,  Yang Li ,  Jun Zhang ,  Oliver Homann ,  Leslie P. Miranda ,  Justin K. Murray ,  Bin Wu ,  Oh Kyu Yoon ,  John Gordon Allen ,  Chawita Netirojjanakul ,  Yuan Cheng

IPC: C12N15/113 ,  A61P9/10 ,  A61P3/06 ,  C07K16/28

CPC classification number: C12N15/1138 ,  A61P3/06 ,  A61P9/10 ,  C07K16/2851 ,  C07K2317/526 ,  C12N2310/14 ,  C12N2310/315 ,  C12N2310/317 ,  C12N2310/321 ,  C12N2310/332 ,  C12N2310/351 ,  C12N2310/3513 ,  C12N2310/321 ,  C12N2310/3521 ,  C12N2310/322 ,  C12N2310/3533 ,  C12N2310/322 ,  C12N2310/3531

Abstract: The present invention relates to RNAi constructs for reducing expression of the ASGR1 gene. Methods of using such RNAi constructs to treat or prevent cardiovascular disease, such as coronary artery disease and myocardial infarction, and to reduce serum non-HDL cholesterol levels are also described.

公开(公告)号：US12214051B2

公开(公告)日：2025-02-04

申请号：US17151045

申请日：2021-01-15

Applicant: Amgen Inc.

Inventor： Yuan Cheng ,  Chawita Netirojjanakul ,  Jerry Ryan Holder ,  Bin Wu ,  James R. Falsey ,  Bradley J. Herberich ,  Kelvin Sham ,  Leslie P. Miranda ,  Shu-Chen Lu ,  Murielle M. Venient-Ellison ,  Shanaka Stanislaus ,  Junming Yie ,  Jing Xu

IPC: A61K47/68 ,  A61K39/395 ,  A61P3/10 ,  C07K16/28

Abstract: Methods of treating metabolic diseases and disorders using a composition comprising an antigen binding protein specific for the GIPR polypeptide conjugated to a GLP-1 receptor agonist are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy. In certain embodiments the composition comprises an antibody or functional fragment thereof comprising a cysteine at one or more conjugation site(s) wherein the GLP-1 receptor agonist is conjugated to the antibody or functional fragment thereof through the side-chain of the cysteine residue.

公开(公告)号：US10344060B2

公开(公告)日：2019-07-09

申请号：US14773756

申请日：2014-03-12

Applicant: AMGEN INC.

Inventor： Justin K. Murray ,  Jerry Ryan Holder ,  Malgorzata Wanska ,  Christopher M. Tegley ,  James R. Falsey ,  Elizabeth M. Doherty ,  Leslie P. Miranda ,  Kaustav Biswas ,  Bin Wu ,  Kelvin Sham ,  Jason C. Long

IPC: C07K14/00 ,  C07K14/435 ,  C07K16/00 ,  C07K19/00 ,  C07K14/46 ,  C07K14/47 ,  A61K38/00 ,  A61K38/16 ,  A61K38/17 ,  A61K47/64 ,  A61K47/68

Abstract: Disclosed is a composition of matter comprising an isolated polypeptide, which is a peripherally-restricted NaV1.7 inhibitor. In some disclosed embodiments, the isolated polypeptide is an inhibitor of NaV1.7. Other embodiments are conjugated embodiments of the inventive composition of matter and pharmaceutical compositions containing the inventive composition of matter. Isolated nucleic acids encoding some embodiments of inventive polypeptides and expression vectors, and recombinant host cells containing them are disclosed. A method of treating or preventing pain is also disclosed.

公开(公告)号：US20130079303A1

公开(公告)日：2013-03-28

申请号：US13681230

申请日：2012-11-19

Applicant: Amgen Inc.

Inventor： Kristin L. ANDREWS ,  Yunxin Y. Bo ,  Shon Booker ,  Victor J. Cee ,  Noel D'Angelo ,  Bradley J. Herberich ,  Fang-Tsao Hong ,  Claire I.M. Jackson ,  Brian Alan Lanman ,  Hongyu Liao ,  Longbin Liu ,  Nobuko Nishimura ,  Mark H. Norman ,  Liping H. Pettus ,  Anthony B. Reed ,  Adrian Leonard Smith ,  Seifu Tadesse ,  Nuria A. Tamayo ,  Bin Wu ,  Ryan Wurz ,  Kevin C. Yang

IPC: C07D473/00 ,  C07D417/14 ,  C07D405/14 ,  C07D413/14 ,  C07D401/14

CPC classification number: C07D473/00 ,  C07D401/14 ,  C07D405/14 ,  C07D413/14 ,  C07D417/14

Abstract: The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt thereof; methods of treating diseases or conditions, such as cancer, using the compounds; and pharmaceutical compositions containing the compounds, wherein the variables are as defined herein.

Abstract translation: 本发明涉及式I化合物或其药学上可接受的盐; 使用该化合物治疗疾病或病症如癌症的方法; 和含有这些化合物的药物组合物，其中变量如本文所定义。

公开(公告)号：US09394297B2

公开(公告)日：2016-07-19

申请号：US14380918

申请日：2013-02-27

Applicant: AMGEN INC.

Inventor： Victor Cee ,  Frank Chavez, Jr. ,  Jian J. Chen ,  Essa Hu Harrington ,  Bradley Herberich ,  Claire L. M. Jackson ,  Brian A. Lanman ,  Thomas T. Nguyen ,  Mark H. Norman ,  Liping H. Pettus ,  Anthony B. Reed ,  Adrian L. Smith ,  Nuria A. Tamayo ,  Andrew Tasker ,  Hui-Ling Wang ,  Bin Wu ,  Ryan Wurz

IPC: C07D401/04 ,  C07D471/04 ,  C07D487/04

CPC classification number: C07D471/04 ,  C07D401/04 ,  C07D487/04

Abstract: The invention relates to amide-containing compounds of formula (1), and salts thereof. In some embodiments, the invention relates to inhibitors or modulators of Pim-1 and/or Pim-2, and/or Pim-3 protein kinase activity or enzyme function. In still further embodiments, the invention relates to pharmaceutical compositions comprising compounds disclosed herein, and their use in the prevention and treatment of Pim kinase related conditions and diseases, preferably cancer.

Abstract translation: 本发明涉及式（1）的含酰胺化合物及其盐。 在一些实施方案中，本发明涉及Pim-1和/或Pim-2和/或Pim-3蛋白激酶活性或酶功能的抑制剂或调节剂。 在另外的实施方案中，本发明涉及包含本文公开的化合物的药物组合物及其在预防和治疗Pim激酶相关病症和疾病，优选癌症中的用途。